The New York Times filed a motion to amend its copyright complaint against Microsoft and OpenAI, alleging that...
The New York Times filed a motion to amend its copyright complaint against Microsoft and OpenAI, alleging that Microsoft actively encouraged copyright infringement by building a bespoke supercomputing system for OpenAI.
MSFT has not made a large direction-matching 30-90 day move yet.
signal brief
The New York Times filed a motion to amend its copyright complaint against Microsoft and OpenAI, alleging that Microsoft actively encouraged copyright infringement by building a bespoke supercomputing system for OpenAI. The motion, reported by Ars Technica, follows a Supreme Court ruling that raised the bar for contributory infringement claims. NYT asserts that Microsoft intentionally induced illegal conduct by providing the infrastructure. Microsoft dismissed the move as 'a last-ditch effort.' This legal escalation could impact Microsoft's AI ambitions and its partnership with OpenAI, potentially slowing data center deployments and affecting suppliers like NVDA, AMD, and AVGO. Competitors such as GOOGL and AMZN may also face increased scrutiny over their AI training practices.
evidence
- https://www.datacenterdynamics.com/en/news/mystery-tech-firm-looks-to-build-800-acre-data-center-campus-outside-grand-rapids-michigan/web
- https://arstechnica.com/tech-policy/2026/06/microsoft-built-supercomputer-to-help-openai-infringe-copyrights-nyt-alleged/web
- https://stackoverflow.com/questions/79965975/obstacles-while-using-azure-devops-to-manage-branches-and-perform-code-reviews-oweb
- https://data.sec.gov/api/xbrl/companyfacts/CIK0000789019.jsonedgar
- https://apps.apple.com/us/app/microsoft-authenticator/id983156458web
- https://manifold.markets/SanghyeonSeo/will-microsoft-power-its-data-centeweb
- https://manifold.markets/oog/will-msft-acquiremerge-with-openaiweb
- https://manifold.markets/ManifoldAI/will-openaimicrosoft-officially-conweb
spillover entities
Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.